Se connecter

Bibliographies thématiques / Dose intensity / Articles de revues

Pour voir les autres types de publications sur ce sujet consultez le lien suivant : Dose intensity.

Articles de revues sur le sujet « Dose intensity »

Auteur : Grafiati

Publié le 9 mars 2023

Mis à jour le 31 juillet 2025

Créez une référence correcte selon les styles APA, MLA, Chicago, Harvard et plusieurs autres

Choisissez une source :

Consultez les 50 meilleurs articles de revues pour votre recherche sur le sujet « Dose intensity ».

À côté de chaque source dans la liste de références il y a un bouton « Ajouter à la bibliographie ». Cliquez sur ce bouton, et nous générerons automatiquement la référence bibliographique pour la source choisie selon votre style de citation préféré : APA, MLA, Harvard, Vancouver, Chicago, etc.

Vous pouvez aussi télécharger le texte intégral de la publication scolaire au format pdf et consulter son résumé en ligne lorsque ces informations sont inclues dans les métadonnées.

Parcourez les articles de revues sur diverses disciplines et organisez correctement votre bibliographie.

1

Ozols, R. F., J. T. Thigpen, J. Dauplat, et al. "Dose intensity." Annals of Oncology 4 (1993): S49—S56. http://dx.doi.org/10.1093/annonc/4.suppl_4.s49.

Texte intégral

Styles APA, Harvard, Vancouver, ISO, etc.

2

SURBONE, ANTONELLA, and VINCENT T. DeVITA. "Dose Intensity." Annals of the New York Academy of Sciences 698, no. 1 Breast Cancer (1993): 279–88. http://dx.doi.org/10.1111/j.1749-6632.1993.tb17219.x.

Texte intégral

Styles APA, Harvard, Vancouver, ISO, etc.

3

Coldman, A. J., and C. M. Coppin. "Calculating dose intensity." Journal of Clinical Oncology 9, no. 9 (1991): 1713–14. http://dx.doi.org/10.1200/jco.1991.9.9.1713.

Texte intégral

Styles APA, Harvard, Vancouver, ISO, etc.

4

Piccart, M. J., L. Biganzoli, and A. Di Leo. "S34 Dose intensity and dose density." European Journal of Cancer 34 (February 1998): S8. http://dx.doi.org/10.1016/s0959-8049(97)89207-6.

Texte intégral

Styles APA, Harvard, Vancouver, ISO, etc.

5

Portlock, C. S. "Dose density and dose intensity: where does CHOP go from here?" Annals of Oncology 13, no. 9 (2002): 1329–30. http://dx.doi.org/10.1093/annonc/mdf238.

Texte intégral

Styles APA, Harvard, Vancouver, ISO, etc.

6

Tonkin, Katia, and Ian Tannock. "Dose Intensity in Chemotherapy." Journal of Clinical Oncology 3, no. 6 (1985): 891. http://dx.doi.org/10.1200/jco.1985.3.6.891.

Texte intégral

Résumé :

To the Editor: In a recent article, Hryniuk and Bush have established a strong correlation between dose intensity of CMF (cyclophosphamide, methotrexate, 5-fluorouracil) chemotherapy, and the rate of tumor response in patients with metastatic breast cancer. They also observed a significant correlation between rate of tumor response and median survival time (r = .66, P < .001). The authors were careful to avoid the conclusion that there was a direct correlation between dose intensity and median survival, but it is surprising that they did not examine this more important relationship directly

Styles APA, Harvard, Vancouver, ISO, etc.

7

Hryniak, William. "Dose Intensity…and Beyond." Cancer Investigation 22, no. 4 (2004): 648–49. http://dx.doi.org/10.1081/cnv-200027172.

Texte intégral

Styles APA, Harvard, Vancouver, ISO, etc.

8

Meyer, R., M. Goodyear, and W. Hryniuk. "Dose intensity and lymphoma." Journal of Clinical Oncology 9, no. 8 (1991): 1511. http://dx.doi.org/10.1200/jco.1991.9.8.1511.

Texte intégral

Styles APA, Harvard, Vancouver, ISO, etc.

9

Coldman, Andrew J., Christopher M. L. Coppin, and James H. Goldie. "Models for dose intensity." Mathematical Biosciences 92, no. 1 (1988): 97–113. http://dx.doi.org/10.1016/0025-5564(88)90007-7.

Texte intégral

Styles APA, Harvard, Vancouver, ISO, etc.

10

Gianni, A. M., and M. J. Piccart. "Optimising chemotherapy dose density and dose intensity." European Journal of Cancer 36 (April 2000): 1–3. http://dx.doi.org/10.1016/s0959-8049(99)00258-0.

Texte intégral

Styles APA, Harvard, Vancouver, ISO, etc.

11

Warde, Nick. "Does the dose intensity of BEP chemotherapy affect survival?" Nature Reviews Urology 7, no. 9 (2010): 477. http://dx.doi.org/10.1038/nrurol.2010.127.

Texte intégral

Styles APA, Harvard, Vancouver, ISO, etc.

12

Dodwell, DJ, H. Gurney, and N. Thatcher. "Dose intensity in cancer chemotherapy." British Journal of Cancer 61, no. 6 (1990): 789–94. http://dx.doi.org/10.1038/bjc.1990.178.

Texte intégral

Styles APA, Harvard, Vancouver, ISO, etc.

13

Cavaletti, G., L. Marzorati, G. Bogliun, et al. "Cisplatin-lnduced peripheral neurotoxicity is dependent on total-dose intensity and single-dose intensity." Cancer 69, no. 1 (1992): 203–7. http://dx.doi.org/10.1002/1097-0142(19920101)69:1<203::aid-cncr2820690133>3.0.co;2-1.

Texte intégral

Styles APA, Harvard, Vancouver, ISO, etc.

14

Costabel, U., SD Nathan, L. Lancaster, et al. "Dose modifications and dose intensity during treatment with pirfenidone." Pneumologie 71, S 01 (2017): S1—S125. http://dx.doi.org/10.1055/s-0037-1598499.

Texte intégral

Styles APA, Harvard, Vancouver, ISO, etc.

15

Livingston, Robert B. "Dose intensity and high dose therapy. Two different concepts." Cancer 74, S3 (1994): 1177–83. http://dx.doi.org/10.1002/1097-0142(19940801)74:3+<1177::aid-cncr2820741529>3.0.co;2-7.

Texte intégral

Styles APA, Harvard, Vancouver, ISO, etc.

16

Levin, L., and W. M. Hryniuk. "Dose intensity analysis of chemotherapy regimens in ovarian carcinoma." Journal of Clinical Oncology 5, no. 5 (1987): 756–67. http://dx.doi.org/10.1200/jco.1987.5.5.756.

Texte intégral

Résumé :

The relationship between outcome and dose intensity was analyzed for first-line chemotherapy of advanced ovarian cancer using a particular CHAP (cyclophosphamide, hexamethylmelamine, Adriamycin [Adria Laboratories, Columbus, OH], cisplatin) regimen as the standard. Previously described techniques were used to calculate the average dose intensity of regimens containing one, two, three, or all four drugs of CHAP, relative to the standard. The average relative dose intensity, especially the relative dose intensity of cisplatin, correlated significantly with clinical response and with median survi

Styles APA, Harvard, Vancouver, ISO, etc.

17

Winkelman, Chris, Abdus Sattar, Hasina Momotaz, et al. "Dose of Early Therapeutic Mobility: Does Frequency or Intensity Matter?" Biological Research For Nursing 20, no. 5 (2018): 522–30. http://dx.doi.org/10.1177/1099800418780492.

Texte intégral

Résumé :

Objective: Investigate the feasibility of a nurse-led mobility protocol and compare the effects of once- versus twice-daily episodes of early therapeutic mobility (ETM) and low- versus moderate-intensity ETM on serum biomarkers of inflammation and selected outcomes in critically ill adults. Design: Randomized interventional study with repeated measures and blinded assessment of outcomes. Setting: Four adult intensive care units (ICUs) in two academic medical centers. Subjects: Fifty-four patients with > 48 hr of mechanical ventilation (MV). Intervention: Patients were assigned to once- or t

Styles APA, Harvard, Vancouver, ISO, etc.

18

Band, Pierre R., Michele Deschamps, and Lucien Israël. "Retinoid Chemoprevention Timing and Dose Intensity." Cancer Investigation 7, no. 2 (1989): 205–10. http://dx.doi.org/10.3109/07357908909038286.

Texte intégral

Styles APA, Harvard, Vancouver, ISO, etc.

19

Cohen, M. H. "What determines actual chemotherapy dose intensity?" Journal of Clinical Oncology 8, no. 11 (1990): 1926. http://dx.doi.org/10.1200/jco.1990.8.11.1926.

Texte intégral

Styles APA, Harvard, Vancouver, ISO, etc.

20

Hryniuk, W. M., and M. Goodyear. "The calculation of received dose intensity." Journal of Clinical Oncology 8, no. 12 (1990): 1935–37. http://dx.doi.org/10.1200/jco.1990.8.12.1935.

Texte intégral

Styles APA, Harvard, Vancouver, ISO, etc.

21

Heller, G., and N. K. Cheung. "Dose-intensity analysis and randomized trials." Journal of Clinical Oncology 9, no. 9 (1991): 1715–16. http://dx.doi.org/10.1200/jco.1991.9.9.1715.

Texte intégral

Styles APA, Harvard, Vancouver, ISO, etc.

22

Ozols, Robert F. "Ovarian Cancer: Is Dose Intensity Dead?" Journal of Clinical Oncology 25, no. 27 (2007): 4157–58. http://dx.doi.org/10.1200/jco.2007.12.1723.

Texte intégral

Styles APA, Harvard, Vancouver, ISO, etc.

23

Cox, J., D. Ball, C. Belani, et al. "Dose intensity in lung cancer treatment." Lung Cancer 10 (March 1994): S11—S13. http://dx.doi.org/10.1016/0169-5002(94)91661-6.

Texte intégral

Styles APA, Harvard, Vancouver, ISO, etc.

24

Sanchis-Gomar, Fabian, Carmen Fiuza-Luces, and Alejandro Lucia. "Exercise Intensity, Dose, and Cardiovascular Disease." JAMA 315, no. 15 (2016): 1658. http://dx.doi.org/10.1001/jama.2016.0306.

Texte intégral

Styles APA, Harvard, Vancouver, ISO, etc.

25

Gregory, S. A., and L. Trümper. "Chemotherapy dose intensity in non-Hodgkin's lymphoma: is dose intensity an emerging paradigm for better outcomes?" Annals of Oncology 16, no. 9 (2005): 1413–24. http://dx.doi.org/10.1093/annonc/mdi264.

Texte intégral

Styles APA, Harvard, Vancouver, ISO, etc.

26

Simon, R., and E. L. Korn. "Selecting Drug Combinations Based on Total Equivalent Dose (Dose Intensity)." JNCI Journal of the National Cancer Institute 82, no. 18 (1990): 1469–76. http://dx.doi.org/10.1093/jnci/82.18.1469.

Texte intégral

Styles APA, Harvard, Vancouver, ISO, etc.

27

Hryniuk, W., E. Frei, and F. A. Wright. "A single scale for comparing dose-intensity of all chemotherapy regimens in breast cancer: summation dose-intensity." Journal of Clinical Oncology 16, no. 9 (1998): 3137–47. http://dx.doi.org/10.1200/jco.1998.16.9.3137.

Texte intégral

Résumé :

PURPOSE To construct a single scale for comparing the dose-intensity of all chemotherapy regimens in breast cancer. MATERIALS AND METHODS First-line single-agent trials in metastatic disease were reviewed. The unit dose-intensity (UDI) that was required to produce a 30% complete response plus partial response (CR + PR) rate was determined for each drug. Randomized trials were then analyzed that prospectively tested dose-intensity. The dose-intensities of the drugs in each arm were expressed as fractions of their UDIs and added together. This yielded each arm's summation dose-intensity (SDI), w

Styles APA, Harvard, Vancouver, ISO, etc.

28

Zelinskiy, A. S., G. A. Yakovlev та D. E. Fil’trov. "Связь мощности дозы гамма-излучения с интенсивностью ливневых осадков". Вестник КРАУНЦ. Физико-математические науки, № 3 (22 листопада 2021): 189–99. http://dx.doi.org/10.26117/2079-6641-2021-36-3-189-199.

Texte intégral

Résumé :

Experimental and theoretical studies of the influence of the intensity, amount and duration of liquid atmospheric precipitation on the formation of γ-background in the surface layer of the atmosphere are presented. It was observed that precipitation causes an increase in the γ-radiation dose rate in the form of bursts. In this case, the total amount of precipitation in an event determines the magnitude of the burst of the dose rate, and the intensity of precipitation determines the rate of increase in the dose rate of γ-radiation. A mathematical model, which establishes a quantitative relation

Styles APA, Harvard, Vancouver, ISO, etc.

29

Campbell, Patrick G., Ian B. Stewart, Anita C. Sirotic, and Geoffrey M. Minett. "Does exercise intensity affect wellness scores in a dose-like fashion?" European Journal of Sport Science 20, no. 10 (2020): 1395–404. http://dx.doi.org/10.1080/17461391.2019.1710264.

Texte intégral

Styles APA, Harvard, Vancouver, ISO, etc.

30

Alghamdi, Mohammed Abdullah, Richard Lee-Ying, Mina Swiha, et al. "The effect of sorafenib (S) starting dose and dose intensity on survival in patients with advanced hepatocellular carcinoma (HCC)." Journal of Clinical Oncology 35, no. 4_suppl (2017): 400. http://dx.doi.org/10.1200/jco.2017.35.4_suppl.400.

Texte intégral

Résumé :

400 Background: The SHARP trial showed that S improves survival in advanced HCC. In clinical practice full dose (FD) of S at 400mg bid can be difficult to tolerate and so a reduced dose (RD) is often required. The purpose of this study was to determine whether starting dose or dose intensity of S affects survival in patients with HCC. Methods: All patients treated with S for HCC in Alberta, Canada from January 2008 to July 2016 were included in this study. Patient demographics, clinical, tumor characteristics, S starting dose and dose intensity were collected and analyzed. Patients were dichot

Styles APA, Harvard, Vancouver, ISO, etc.

31

Lutfi, Forat, Rohit Boshnoi, Vikas Patel, et al. "Bleeding and Thrombotic Risk in Low Dose Heparin Infusion As Compared to Standard Dose Heparin Infusion." Blood 132, Supplement 1 (2018): 1251. http://dx.doi.org/10.1182/blood-2018-99-110232.

Texte intégral

Résumé :

Abstract Introduction: At our institution, therapeutic use of unfractionated heparin (UFH) is administered by standard (target anti-Xa activity level 0.30 to 0.70 IU/mL) and low intensity (target anti-Xa activity level 0.25 to 0.35 IU/mL) protocols. In patients deemed high-risk for hemorrhage, the low intensity protocol is often employed. However, to date, there has been little study of differences in adverse events, namely hemorrhage, and efficacy between intensity protocols. Furthermore, identifying the effect of patient specific factors (e.g. age, indication for UFH, anticoagulant and antip

Styles APA, Harvard, Vancouver, ISO, etc.

32

Meyer, R. M., W. M. Hryniuk, and M. D. Goodyear. "The role of dose intensity in determining outcome in intermediate-grade non-Hodgkin's lymphoma." Journal of Clinical Oncology 9, no. 2 (1991): 339–47. http://dx.doi.org/10.1200/jco.1991.9.2.339.

Texte intégral

Résumé :

To determine whether the dose intensity of chemotherapeutic regimens correlates with the complete remission rate in adult patients with advanced-stage intermediate-grade lymphoma, reports of comparative trials of therapy were reviewed. Reports were identified using MEDLINE, through references from review articles, and through review of selected abstracts. Twenty-two studies including 14 randomized and eight cohort trials were analyzed to assess projected dose intensity. Four other studies were analyzed to assess the role of received dose intensity. Dose intensities were calculated using descri

Styles APA, Harvard, Vancouver, ISO, etc.

33

Leavey, Patrick J., Elpis Mantadakis, and Gerhard Maale. "VARIABILITY IN DOSE INTENSITY OF HIGH-DOSE METHOTREXATE FOR NONMETASTATIC OSTEOSARCOMA." Pediatric Hematology and Oncology 19, no. 7 (2002): 483–89. http://dx.doi.org/10.1080/08880010290097305.

Texte intégral

Styles APA, Harvard, Vancouver, ISO, etc.

34

Dembo, A. J. "Time-dose factors in chemotherapy: expanding the concept of dose-intensity." Journal of Clinical Oncology 5, no. 5 (1987): 694–96. http://dx.doi.org/10.1200/jco.1987.5.5.694.

Texte intégral

Styles APA, Harvard, Vancouver, ISO, etc.

35

Jensen, Randy L., Merideth M. Wendland, Shyh-Shi Chern, and Dennis C. Shrieve. "NOVALIS INTENSITY-MODULATED RADIOSURGERY." Neurosurgery 62, suppl_5 (2008): A2—A10. http://dx.doi.org/10.1227/01.neu.0000325931.26531.45.

Texte intégral

Résumé :

ABSTRACT OBJECTIVE The Novalis stereotactic radiotherapy system (BrainLAB, Heimstetten, Germany) allows for precise treatment of cranial base tumors with single-fraction radiosurgery. In some cases, however, proximity of the optic nerve and chiasm is a concern. In these cases, intensity-modulated stereotactic radiosurgery (IMRS) can be used to limit the dose to these structures. IMRS planning can be labor intensive, which poses a problem when it is performed on the day of treatment. We describe our methods and results of preprocedure planning for IMRS for patients with lesions in the cavernous

Styles APA, Harvard, Vancouver, ISO, etc.

36

Smith, Malcolm, Jeffrey Abrams, Edward L. Trimble, and Richard S. Ungerleider. "Dose Intensity of Chemotherapy for Childhood Cancers." Oncologist 1, no. 5 (1996): 293–304. http://dx.doi.org/10.1634/theoncologist.1-5-293.

Texte intégral

Styles APA, Harvard, Vancouver, ISO, etc.

37

de Vries, E. G. E., T. C. Hamilton, M. Lind, J. Dauplat, J. P. Neijt, and R. F. Ozols. "Drug resistance, supportive care and dose intensity." Annals of Oncology 4 (1993): S57—S62. http://dx.doi.org/10.1093/annonc/4.suppl_4.s57.

Texte intégral

Styles APA, Harvard, Vancouver, ISO, etc.

38

Thigpen, J. T. "Dose-intensity in ovarian carcinoma: hold, enough?" Journal of Clinical Oncology 15, no. 4 (1997): 1291–93. http://dx.doi.org/10.1200/jco.1997.15.4.1291.

Texte intégral

Styles APA, Harvard, Vancouver, ISO, etc.

39

Cohen, M. H. "MOPP dose intensity and survival: flawed analysis." Journal of Clinical Oncology 8, no. 4 (1990): 756–57. http://dx.doi.org/10.1200/jco.1990.8.4.756.

Texte intégral

Styles APA, Harvard, Vancouver, ISO, etc.

40

Anderson, J. R., and P. F. Coccia. "Is more better? Dose intensity in neuroblastoma." Journal of Clinical Oncology 9, no. 6 (1991): 902–4. http://dx.doi.org/10.1200/jco.1991.9.6.902.

Texte intégral

Styles APA, Harvard, Vancouver, ISO, etc.

41

Eijsvogels, Thijs M. H., and Paul D. Thompson. "Exercise Intensity, Dose, and Cardiovascular Disease—Reply." JAMA 315, no. 15 (2016): 1659. http://dx.doi.org/10.1001/jama.2016.0312.

Texte intégral

Styles APA, Harvard, Vancouver, ISO, etc.

42

Alghamdi, Mohammed Abdullah, Richard Lee-Ying, Hao-Wen Sim, et al. "Effect of sorafenib (S) starting dose and dose intensity on survival in patients with hepatocellular carcinoma (HCC): Results from a Canadian multicenter HCC database." Journal of Clinical Oncology 35, no. 15_suppl (2017): 4084. http://dx.doi.org/10.1200/jco.2017.35.15_suppl.4084.

Texte intégral

Résumé :

4084 Background: The SHARP trial showed that S improves survival in advanced HCC. Full dose (FD) S at 400mg bid can be difficult to tolerate, so some clinicians begin with a reduced dose (RD) & escalate as tolerated to maximum dose. The purpose of this study was to determine whether starting dose or dose intensity of S affects survival. Methods: All patients treated with S for HCC from 01/2008 to 06/2016 in British Columbia, Alberta, Ontario (Princess Margaret Cancer Centre & Sunnybrook Odette Cancer Centre), were included. Patient demographics, clinical, tumor characteristics, S start

Styles APA, Harvard, Vancouver, ISO, etc.

43

Stewart, Clinton F. "Pharmacodynamics and Cancer: Practical Aspects of Dose Intensity for Pharmacists." Journal of Pharmacy Practice 4, no. 1 (1991): 11–19. http://dx.doi.org/10.1177/089719009100400103.

Texte intégral

Résumé :

Recent clinical studies have suggested that dose or dose intensity may be a critical factor in achieving an optimal effect from cancer chemotherapy in tumors that are chemosensitive. This article reviews the rationale for the importance of drug dose in cancer chemotherapy and methods of expressing dose intensity. Several clinical studies that provide evidence of the importance of dose intensity are reviewed. The concept of systemic intensity of cancer chemotherapy is discussed. Finally, the practical aspects of dose intensity for the pharmacist are addressed, including dosage calculation, drug

Styles APA, Harvard, Vancouver, ISO, etc.

44

Ang, P. T., A. U. Buzdar, T. L. Smith, S. Kau, and G. N. Hortobagyi. "Analysis of dose intensity in doxorubicin-containing adjuvant chemotherapy in stage II and III breast carcinoma." Journal of Clinical Oncology 7, no. 11 (1989): 1677–84. http://dx.doi.org/10.1200/jco.1989.7.11.1677.

Texte intégral

Résumé :

Three hundred thirty-six patients with stage II or stage III breast cancer were treated on an adjuvant protocol containing fluorouracil, doxorubicin, cyclophosphamide, vincristine, and prednisone (FACVP). Depending on the estrogen-receptor (ER) status, the patients were subdivided to receive maintenance chemotherapy with or without tamoxifen. The administered dose intensity of fluorouracil, doxorubicin, and cyclophosphamide (FAC) (mg/m2/wk) relative to the projected dose intensity (based on planned dose) was computed for each patient. The relative dose intensity of the first six cycles of chem

Styles APA, Harvard, Vancouver, ISO, etc.

45

Murthy, Vedang, Shirley Lewis, Mayur Sawant, Siji N. Paul, Umesh Mahantshetty, and Shyam Kishore Shrivastava. "Incidental Dose to Pelvic Nodal Regions in Prostate-Only Radiotherapy." Technology in Cancer Research & Treatment 16, no. 2 (2016): 211–17. http://dx.doi.org/10.1177/1533034616661447.

Texte intégral

Résumé :

Objectives: Pelvic lymph nodal regions receive an incidental dose from conformal treatment of the prostate. This study was conducted to investigate the doses received by the different pelvic nodal regions with varying techniques used for prostate radiotherapy. Methods and Materials: Twenty patients of high-risk node-negative prostate cancer treated with intensity-modulated radiotherapy to the prostate alone were studied. Replanning was done for intensity-modulated radiotherapy, 3-dimensional conformal treatment, and 2-dimensional conventional radiotherapy with additional delineation of the pel

Styles APA, Harvard, Vancouver, ISO, etc.

46

Komuro, Ayumi, Sachiko Seo, Nobuo Mochizuki, Yosuke Minami, and Toshikatu Kawasaki. "Impact of Total Dose Intensity and Relative Dose Intensity (RDI) of R-CHOP on Survival in Patients with DLBCL." Blood 132, Supplement 1 (2018): 4218. http://dx.doi.org/10.1182/blood-2018-99-114227.

Texte intégral

Résumé :

Abstract Background: The standard chemotherapy for diffuse large B-cell lymphoma (DLBCL) is CHOP combined with rituximab (R-CHOP). The guidelines (e.g. NCCN or ESMO) recommend six to eight courses of R-CHOP and the optimal number of courses is still unclear. The relative dose intensity (RDI) was proposed as an indicator for both dose intensity and interval. The previous studies have reported the relation between RDI of CHOP or R-CHOP and treatment outcomes. However, little is known about the low threshold of RDI that affects survival and few studies have compared between RDI and total dose of

Styles APA, Harvard, Vancouver, ISO, etc.

47

LeVasseur, N., and S. K. Chia. "Sequential versus concurrent chemotherapy for adjuvant breast cancer: does dose intensity matter?" British Journal of Cancer 117, no. 2 (2017): 157–58. http://dx.doi.org/10.1038/bjc.2017.176.

Texte intégral

Styles APA, Harvard, Vancouver, ISO, etc.

48

Lin, Ruihe, Jie Shan, Taize Yuan, and Chaonan Qian. "Dosimetric comparison of intensity-modulated proton radiotherapy versus intensity-modulated photon-based radiotherapy for breast cancer." Visualized Cancer Medicine 2 (2021): 5. http://dx.doi.org/10.1051/vcm/2021002.

Texte intégral

Résumé :

Purpose: This study aims to compare the dosimetric differences in intensity-modulated proton therapy (IMPT) using pencil beam scanning technology and intensity-modulated photon-based radiotherapy (IMRT) in hypofractionated whole-breast irradiation (HF-WBI) and find out the more beneficial technique. Methods and Materials: Eight breast cancer (BC) patients with pathological stage T1 ~ 2N0M0 were immobilized and underwent 4D-CT scanning used deep inspiration breath-hold (DIBH) technology. The IMPT and IMRT plans were designed for each patient. The IMPT plans used two en-face beam angles. IMRT pl

Styles APA, Harvard, Vancouver, ISO, etc.

49

Meyer, R. M., G. P. Browman, M. L. Samosh, et al. "Randomized phase II comparison of standard CHOP with weekly CHOP in elderly patients with non-Hodgkin's lymphoma." Journal of Clinical Oncology 13, no. 9 (1995): 2386–93. http://dx.doi.org/10.1200/jco.1995.13.9.2386.

Texte intégral

Résumé :

PURPOSE To determine whether modifying the standard regimen of cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) from full doses given every 3 weeks to one-third doses given weekly (chop) increases the received chemotherapy dose-intensity in elderly patients with advanced-stage intermediate-grade lymphoma. PATIENTS AND METHODS Consenting patients, age > or = 65 years who had acceptable cardiac, renal, and liver function and an Eastern Cooperative Oncology Group (ECOG) performance status less than 4, were stratified by bone marrow and performance status and randomized to rece

Styles APA, Harvard, Vancouver, ISO, etc.

50

Lewis, Ian J., Simon Weeden, David Machin, Dan Stark, and Alan W. Craft. "Received Dose and Dose-Intensity of Chemotherapy and Outcome in Nonmetastatic Extremity Osteosarcoma." Journal of Clinical Oncology 18, no. 24 (2000): 4028–37. http://dx.doi.org/10.1200/jco.2000.18.24.4028.

Texte intégral

Résumé :

PURPOSE: To examine the relationship between received dose, received dose-intensity (RDI), and survival in patients with osteosarcoma. PATIENTS AND METHODS: Between 1983 and 1993, the European Osteosarcoma Intergroup (EOI) conducted two randomized trials involving patients with high-grade, nonmetastatic, biopsy-proven osteosarcoma of the extremity. These trials shared a common treatment arm of doxorubicin (DOX) 75 mg/m2 and cisplatin (CDDP) 100 mg/m2 planned for six cycles at 3-week intervals. Definitive surgery was scheduled at week 9, after three cycles. Survival time was calculated from 122

Styles APA, Harvard, Vancouver, ISO, etc.

Nous offrons des réductions sur tous les plans premium pour les auteurs dont les œuvres sont incluses dans des sélections littéraires thématiques. Contactez-nous pour obtenir un code promo unique!